...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BMC Health Services Research >Pharmacist-led intervention in treatment non-adherence and associated direct costs of management among ambulatory patients with type 2 diabetes in southwestern Nigeria
【24h】

Pharmacist-led intervention in treatment non-adherence and associated direct costs of management among ambulatory patients with type 2 diabetes in southwestern Nigeria

机译：药剂师LED干预治疗尼日利亚西南部2型糖尿病患者的非遵守和相关直接成本

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Non-adherence to recommended therapy remains a challenge to achieving optimal clinical outcome with resultant economic implications. To evaluate the effect of a pharmacist-led intervention on treatment non-adherence and direct costs of management among patients with type 2 diabetes (T2D). A quasi-experimental study among 201-patients with T2D recruited from two-tertiary healthcare facilities in southwestern Nigeria using semi-structured interview. Patients were assigned into control (HbA1c??7%, n?=?95) and intervention (HbA1c?≥?7%, n?=?106) groups. Baseline questionnaire comprised modified 4-item Medication Adherence Questions (MAQ), Perceived Dietary Adherence Questionnaire (PDAQ) and International Physical Activity Questionnaire, to assess participants’ adherence to medications, diet and physical activity, respectively. Post-baseline, participants were followed-up for 6-month with patient-specific educational intervention provided to resolve adherence discrepancies in the intervention group only, while control group continued to receive usual care. Subsequently, direct costs of management for 6-month pre-baseline and 6-month post-baseline were estimated for both groups. Data were summarized using descriptive statistics. Chi-square, McNemar and paired t-test were used to evaluate categorical and continuous variables at p??0.05. Mean age was 62.9?±?11.6?years, and 160(79.6%) were females. Glycated haemoglobin (HbA1c) was 6.1?±?0.6% (baseline) and 6.1?±?0.8% at 6-month post-baseline (p?=?0.094) for control group, and 8.7?±?1.5% (baseline) versus 7.8?±?2.0% (6-month), p??0.001, for the intervention. Post-baseline, response to MAQ items 1 (p?=?0.017) and 2 (p??0.001) improved significantly for the intervention. PDAQ score increased significantly from 51.8?±?8.8 at baseline to 56.5?±?3.9 at 6-month (p??0.001) for intervention, and from 56.3?±?4.0 to 56.5?±?3.9 (p?=?0.094) for the control group. Physical activity increased from 775.2?±?700.5 Metabolic Equivalent Task (MET) to 829.3?±?695.5MET(p??0.001) and from 901.4?±?743.5MET to 911.7?±?752.6MET (p?=?0.327) for intervention and control groups, respectively. Direct costs of management per patient increased from USD 327.3?±?114.4 to USD 333.0?±?118.4 (p?=?0.449) for the intervention, while it decreased from USD 290.1?±?116.97 to USD289.1?±?120.0 (p?=?0.89) for control group, at baseline and 6-month post-baseline, respectively. Pharmacist-led intervention enhanced adherence to recommended medications, diet and physical activity among the intervention patients, with a corresponding significant improvement in glycaemic outcome and an insignificant increase in direct costs of management. There is a need for active engagement of pharmacists in management of patients with diabetes in clinical practice. ClinicalTrials.gov identifier: NCT04712916 . Retrospectively-registered.
机译：不遵守推荐的治疗仍然是实现具有所得经济影响的最佳临床结果的挑战。评价药剂师LED干预对2型糖尿病患者治疗非粘附性和管理直接成本的影响（T2D）。二等医疗机构在西南西南三级医疗机构中招募了两次患有的201-患者的准实验研究。患者被分配到对照中（HBA1C？7％，n？=β95）和干预（HBA1c？≥？7％，n？= 106）组。基线调查表包括修饰的4项药物申请问题（MAQ），感知膳食依从性问卷（PDAQ）和国际身体活动问卷，分别评估参与者的依从药物，饮食和身体活动。后基线，参与者随访6个月，患者特定的教育干预仅提供，以解决干预组中的依从性差异，而对照组继续接受通常的护理。随后，两组估计了6个月前基线和6个月后3个月后的直接费用。数据总结了使用描述性统计数据。 Chi-Square，McNemar和配对T检验用于评估P = 0.05的P = 0.05的分类和连续变量。平均年龄为62.9？±11.6？年，160（79.6％）是女性。糖化血红蛋白（HBA1c）为6.1〜±0.6％（基线）和6.1？±0.8％，在6个月后的基线（p？= 0.094），对照组，8.7？±1.5％（基线）与7.8？±2.80％（6个月），p？<0.001，用于干预。后基线，对MAQ项的响应1（p？= 0.017）和2（p≤≤0.001）显着改善了干预。 PDAQ得分从51.8±8.8在基线上显着增加到56.5？±3.9，在6个月（p≤≤0.001），介入，56.3？±4.0至56.5？±3.9（p？=对照组0.094）。体育活动从775.2增加到±700.5代谢等效任务（MET）到829.3？±695.5met（P？＆Δ0.001），从901.4？743.5met到911.7？752.6met（p？=？ 0.327分别用于干预和对照组。每位患者的管理的直接成本从327.3美元增加到333.0美元？±118.4美元？±118.4（p？= 0.449），而它从290.1 u-α±116.97到USD289.1？±120.0 （P？= 0.89）对对照组，分别为基线和6个月后基线。药剂师主导的干预措施增强了干预患者的推荐药物，饮食和身体活动的依从性，血糖结果具有相应的显着改善，并且管理直接成本的微不足道的增加。有必要积极参与药剂师在临床实践中患有糖尿病患者的管理。 ClinicalTrials.gov标识符：NCT04712916。回顾性地注册。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号